The China Alzheimer’s disease diagnostics market was valued at USD 287.76 million in 2023 and is projected to reach USD 631.73 million by 2030, expanding at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2030. This strong market growth is being driven by several converging factors that are reshaping the landscape of neurological diagnostics in China.

One of the primary growth drivers is the increasing prevalence of Alzheimer’s disease (AD) in China, largely due to the country’s rapidly aging population. As the number of elderly individuals rises, so does the incidence of cognitive disorders, particularly Alzheimer’s disease, which has become a major public health concern.

Another key factor supporting market expansion is the growing reliance on biomarkers for early and accurate disease diagnosis. Biomarkers such as amyloid beta and tau proteins are increasingly being used to identify, track, and monitor disease progression, offering clinicians more precise tools than traditional symptom-based assessments. This trend is particularly relevant in China, where early detection is crucial in managing the rising disease burden.

In addition, the widespread adoption of personalized diagnostic solutions is propelling demand for tailored approaches to Alzheimer’s detection and monitoring. Precision diagnostics help in developing customized treatment plans, improving outcomes and quality of life for patients. The role of technological advancements in medical imaging cannot be understated. Innovations in imaging modalities such as PET (positron emission tomography) and MRI (magnetic resonance imaging) are enabling non-invasive, accurate, and early diagnosis of Alzheimer’s-related brain changes. These technologies are becoming more widely adopted in hospitals, research institutes, and specialized diagnostic centers across China.

Furthermore, the increased government investment in healthcare infrastructure and escalating research and development (R&D) activities in neurology and diagnostics are providing a supportive environment for market growth. China’s health authorities are actively prioritizing neurodegenerative disease research and funding initiatives that enhance diagnostic capabilities.

Key Market Trends & Insights:

• In 2023, imaging techniques held the largest revenue share of 41.40%, reflecting the critical role of neuroimaging in identifying brain changes associated with Alzheimer’s. The demand for technologies such as PET and MRI scans is growing rapidly, especially as clinicians seek early and definitive diagnosis.
• The biomarkers segment is anticipated to witness the fastest growth, registering a CAGR of 15.7% during the forecast period. The rising awareness and adoption of biomarker testing through cerebrospinal fluid (CSF) analysis or blood-based tests underscore its increasing importance in monitoring disease progression and predicting therapeutic responses.
• The diagnosis segment dominated the market in 2023, accounting for 53.49% of total market share. This reflects the growing demand for accurate diagnostic solutions as China’s elderly population grows and the healthcare system becomes more proactive in detecting neurodegenerative diseases at early stages.
• The expansion of public awareness campaigns, government health initiatives, and collaborations with NGOs and healthcare providers have further increased public knowledge and screening rates, contributing to the growth of diagnostic services.
• In terms of end users, academic and research institutes emerged as the leading segment in 2023, contributing 47.02% of the market share. This dominance is largely due to the surge in research studies and clinical trials focusing on neurological diseases over the past decade.
• These institutions are playing a pivotal role in innovative diagnostics research, validating new biomarkers, and testing emerging imaging techniques, which makes them critical contributors to the evolution of Alzheimer’s diagnostics in China.

Order a free sample PDF of the China Alzheimer’s Disease Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 287.76 Million
• 2030 Projected Market Size: USD 631.73 Million
• CAGR (2024-2030): 12.1%

Key Companies & Market Share Insights:

Some key players operating in the market include Quest Diagnostics Incorporated, Abbott, F. Hoffmann-La Roche Ltd., Eli Lily, Bio-Rad Laboratories, Inc., Eisai Co Ltd, Clario, and others. The market is highly competitive, with many manufacturers accounting for most of the share. New source developments, mergers and acquisitions, and collaborations are major strategies these players adopt to counter stiff competition.

Key Players

• Quest Diagnostics
• Labcorb
• C2N diagnostics
• FujireBio
• Bristol Myers Squibb
• Hoffmann-La Roche
• Quanterix
• Sysmex
• Lantheus
• Siemens Healthineers
• Life Molecular Imaging

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the China Alzheimer’s disease diagnostics market is undergoing significant transformation, driven by an aging population, early-stage disease burden, government support, technological innovation, and major pharmaceutical advancements such as the introduction of LEQEMBI. As early detection becomes increasingly central to Alzheimer’s management, demand for advanced diagnostics tools from biomarkers to imaging will continue to expand, ensuring robust market growth through 2030.